Iron chelation in the treatment of cancer: a new role for deferasirox? (Q38112400)

29 August 2017

title

Iron chelation in the treatment of cancer: a new role for deferasirox? (English)

1 reference

29 August 2017

3

Richard D Horniblow

1 reference

29 August 2017

Matthew R Bedford

1

1 reference

29 August 2017

Samuel J Ford

series ordinal

2

1 reference

29 August 2017

Tariq H Iqbal

series ordinal

4

1 reference

29 August 2017

Chris Tselepis

series ordinal

5

1 reference

29 August 2017

publication date

6 June 2013

1 reference

The Journal of Clinical Pharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

53

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

885-891

1 reference

The evolution of iron chelators for the treatment of iron overload disease and cancer.

29 August 2017

cites work

1 reference

Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo

21 January 2018

1 reference

Iron and the anaemia of chronic disease: a review and strategic recommendations.

21 January 2018

1 reference

Iron availability increases the pathogenic potential of Salmonella typhimurium and other enteric pathogens at the intestinal epithelial interface

21 January 2018

1 reference

Iron mobilization using chelation and phlebotomy

21 January 2018

1 reference

The role of oxidant injury in the pathophysiology of human thalassemias

21 January 2018

1 reference

Iron status and risk of cardiovascular disease.

21 January 2018

1 reference

The metallobiology of Alzheimer's disease

21 January 2018

1 reference

Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal

21 January 2018

1 reference

The iron metabolism of neoplastic cells: alterations that facilitate proliferation?

21 January 2018

1 reference

Influence of dietary iron overload on cell proliferation and intestinal tumorigenesis in mice.

21 January 2018

1 reference

Effects of selenium on colon carcinogenesis induced by azoxymethane and dextran sodium sulfate in mouse model with high-iron diet

21 January 2018

1 reference

An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload.

21 January 2018

1 reference

Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma

21 January 2018

1 reference

Modulation of iron transport proteins in human colorectal carcinogenesis

21 January 2018

1 reference

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

21 January 2018

1 reference

Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer

21 January 2018

1 reference

Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial

21 January 2018

1 reference

Novel chelators for cancer treatment: where are we now?

21 January 2018

1 reference

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

21 January 2018

1 reference

The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).

21 January 2018

1 reference

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

21 January 2018

1 reference

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

21 January 2018

1 reference

Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells

21 January 2018

1 reference

Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma

21 January 2018

1 reference

Antiproliferative effect of deferiprone on the Hep G2 cell line

21 January 2018

1 reference

Iron withdrawal strategies fail to prevent the growth of SiHa-induced tumors in mice

21 January 2018

1 reference

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

21 January 2018

1 reference

Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.

21 January 2018

1 reference

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen

21 January 2018

1 reference

Development of tridentate iron chelators: from desferrithiocin to ICL670.

21 January 2018

1 reference

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

21 January 2018

1 reference

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

21 January 2018

1 reference

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

21 January 2018

1 reference

Efficacy and safety of deferasirox in myelodysplastic syndromes

21 January 2018

1 reference

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox

21 January 2018

1 reference

Effect of iron chelators on proliferation and iron uptake in hepatoma cells

21 January 2018

1 reference

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo

21 January 2018

1 reference

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

21 January 2018

1 reference

Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

21 January 2018

1 reference

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism

21 January 2018

1 reference

A perspective of polyamine metabolism

21 January 2018

1 reference

The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.

21 January 2018

1 reference

Human ICE/CED-3 protease nomenclature

21 January 2018

1 reference

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

21 January 2018

1 reference

Nuclear factor-kappaB: the enemy within

21 January 2018

1 reference

Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression

21 January 2018

1 reference

Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen

21 January 2018

1 reference

Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth

21 January 2018

1 reference

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

21 January 2018

1 reference

21 January 2018

mTOR and cancer therapy

1 reference

REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.

21 January 2018

1 reference

Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.

21 January 2018

1 reference

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review

21 January 2018

1 reference

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

21 January 2018

1 reference

Donation Frequency, Iron Loss, and Risk of Cancer Among Blood Donors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.113

1 reference

29 August 2017

1 reference